Clinicopathological and molecular characteristics of primary pulmonary choriocarcinoma: a case report and systematic review
-
By
-
Yixin Liu
-
Xin Lv
-
Shu Su
-
Fangjun Chen
-
Lifeng Wang
-
June 30, 2026
-
Clinical Scorecard: Molecular and Clinicopathological Features of Primary Pulmonary Choriocarcinoma: A Case Study and Comprehensive Review
At a Glance
| Category | Detail |
|---|
| Condition | Primary Pulmonary Choriocarcinoma |
| Key Mechanisms | Loss-of-function or deleterious alterations in TP53, STK11, KEAP1, and SMARCA4. |
| Target Population | Patients with primary pulmonary choriocarcinoma, particularly those with advanced disease. |
| Care Setting | Oncology and multidisciplinary care settings. |
Key Highlights
- PPC is a rare and aggressive non-gestational trophoblastic malignancy.
- Standard treatment for PPC has not been established.
- Molecular profiling suggests distinct characteristics from gestational choriocarcinoma.
- Multimodal treatment including immunotherapy may warrant further investigation.
- The patient experienced disease progression despite initial treatment response.
Guideline-Based Recommendations
Diagnosis
- Diagnosis typically requires pathological confirmation following imaging studies.
Management
- Consider multimodal treatment including chemotherapy and immunotherapy.
Monitoring & Follow-up
- Regular imaging and serum beta-hCG levels to assess treatment response.
Risks
- High risk of early metastasis and poor response to conventional chemotherapy.
Patient & Prescribing Data
A 61-year-old male with advanced PPC and brain metastases.
Combination therapy with albumin-bound paclitaxel, cisplatin, etoposide, capecitabine, and camrelizumab was utilized.
Clinical Best Practices
- Conduct thorough imaging and pathological evaluation for diagnosis.
- Utilize a multidisciplinary approach for treatment planning.
- Monitor for treatment-related adverse effects and adjust therapy as needed.
Related Resources & Content
